Type 1 diabetes, diabetic retinopathy Nutritional, Metabolic, Endocrine
Conditions
Interventions
We sampled type 1 diabetic patients aged 5 to 18 years with early-stage diabetic retinopathy. After 1:3 randomization, two groups were formed: group 1 used continuous glucose monitoring (CGM) with Dex
Sponsors
University Clinic of Kinshasa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Children under 18 years of age, of both sexes, followed in the six diabetic clinics in Kinshasa 2. Known diabetic with diabetic retinopathy 3. No-sickle cell children 4. Informed consent from parents
Exclusion criteria
Exclusion criteria: 1. Age over 18 years 2. Non-type1 diabetes millitus 3. Non-consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Hb1Ac levels measured using the Siemens DCA VANTAGE analyzer at months 1, 3, 6, 9, and 12 2. Microalbuminuria measured using the Siemens DCA VANTAGE analyzer at months 1, 3, 6, 9, and 12 3. Stages of diabetic retinopathy measured using the 2016 standards for screening and surveillance of ocular complications in people with diabetes at months 1 and 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Glycemic average measured using the following standard formula: Hb1ac (in %) x 1.59 - 2.59 at months 1, 3, 6, 9, and 12 2. Time in range (TIR) measured using a Dexcom ONE MCG sensor at months 1, 3, 6, 9, and 12 3. Body mass index (BMI) calculated by dividing weight in kg by height in cm squared at months 1, 3, 6, 9, and 12 | — |
Countries
Congo, Democratic Republic
Contacts
Public ContactCelestin NSIBU
Outcome results
None listed